Spotting the path forward
Early developmental therapeutics is often akin to finding Nemo or spotting the hidden nuggets in the wild
In our latest look at novel agents in Developmental Therapeutics, we discuss some of the inherent challenges many companies face when conducting phase 1 research through the lens of Syros’s progress with their early stage agent targeting both transcription and cell cycle arrest.
Finding a balance between efficacy and tolerability is often much trickier than many outside observers realise, but it can be done.
Of course, this is before we even consider which tumour types might be optimal to pursue in further trials…
BSB subscribers can read more on our latest update and commentary from the ESMO conference – you can log-in or click to access our latest analysis.
This content is restricted to subscribers
